These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1256 related articles for article (PubMed ID: 34744510)

  • 81. Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer.
    Ma S; Wang L
    Front Oncol; 2024; 14():1396843. PubMed ID: 38978733
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis.
    Jiang W; Chen Y; Huang J; Xi D; Chen J; Shao Y; Xu G; Ying W; Wei J; Chen J; Ning Z; Gu W; Pei H
    Oncotarget; 2017 Sep; 8(39):66075-66086. PubMed ID: 29029493
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
    Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Predictive Values of Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Long-Term Survival in High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Single-Centre Retrospective Study.
    Bi H; Shang Z; Jia C; Wu J; Cui B; Wang Q; Ou T
    Cancer Manag Res; 2020; 12():9471-9483. PubMed ID: 33061634
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
    Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer.
    Wang D; Guo D; Shi F; Zhu Y; Li A; Kong L; Teng F; Yu J
    Future Oncol; 2019 Oct; 15(29):3367-3379. PubMed ID: 31424272
    [No Abstract]   [Full Text] [Related]  

  • 90. Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.
    Liu P; Jiang Y; Zheng X; Pan B; Xiang H; Zheng M
    Pathol Oncol Res; 2022; 28():1610294. PubMed ID: 35570842
    [No Abstract]   [Full Text] [Related]  

  • 91. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
    Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prognostic value of nomogram based on pre-treatment inflammatory markers in patients with pulmonary-only synchronous metastases from colorectal cancer.
    Chen L; Li Q; Wang Y; Yang J; Ma X
    Int Immunopharmacol; 2019 Dec; 77():106001. PubMed ID: 31734191
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Systemic immune-inflammation index for predicting prognosis of colorectal cancer.
    Chen JH; Zhai ET; Yuan YJ; Wu KM; Xu JB; Peng JJ; Chen CQ; He YL; Cai SR
    World J Gastroenterol; 2017 Sep; 23(34):6261-6272. PubMed ID: 28974892
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis.
    Wang Y; Li Y; Chen P; Xu W; Wu Y; Che G
    Ann Transl Med; 2019 Sep; 7(18):433. PubMed ID: 31700869
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    Tang R; Deng JP; Zhang L; Zhang WW; Sun JY; Chi F; Zhang J; Wu SG; He ZY
    BMC Cancer; 2022 Mar; 22(1):234. PubMed ID: 35241010
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study.
    Yekedüz E; Dogan İ; Kaya DM; Özgür İ; Utkan G; Vatansever S; Demirci S; Akbulut H; Ürün Y
    J Gastrointest Cancer; 2022 Dec; 53(4):870-879. PubMed ID: 34845631
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis.
    Geng Y; Shao Y; Zhu D; Zheng X; Zhou Q; Zhou W; Ni X; Wu C; Jiang J
    Sci Rep; 2016 Dec; 6():39482. PubMed ID: 28000729
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
    Yücel KB; Yekedüz E; Karakaya S; Tural D; Ertürk İ; Erol C; Ercelep Ö; Öztaş NŞ; Arslan Ç; Uçar G; Küçükarda A; Sever ÖN; Kılıçkap S; Can O; Yazgan SC; Öksüzoğlu B; Karadurmuş N; Şendur MA; Ürün Y
    Sci Rep; 2022 Oct; 12(1):16559. PubMed ID: 36192500
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy.
    Ekinci F; Balcik OY; Demir B; Gursoy P; Ozveren A; Erdogan AP
    J Coll Physicians Surg Pak; 2022 Aug; 32(8):996-1003. PubMed ID: 35932122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.